Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 15 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 5 pages · English

Summary by 6ix AI

The first product is a generic treatment for canine urinary incontinence, providing cost-effective relief for aging dogs. The second product is an affordable formulation of Furosemide tablets, aimed at managing heart conditions in dogs and cats. Both products are designed to enhance accessibility and affordability of veterinary care for pet owners and professionals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases